BridgeBio Pharma, Inc. (NASDAQ:BBIO)
About the company
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|BridgeBio Pharma, Inc.||BBIO||3660.85||41.00||9.64||-12.61||-718.08|
|Taro Pharmaceutical Industries Ltd.||TARO||2563.10||645.00||1.23||10.62||37.88|
|Abeona Therapeutics, Inc.||ABEO||176.70||3.00||1.80||-1.74||75.95|
|Kindred Biosciences, Inc.||KIN||162.63||4.00||2.71||-2.38||None|
|Cocrystal Pharma, Inc.||COCP||53.55||2.00||1.96||-0.92||-733.84|
|China Pharma Holdings, Inc.||CPHI||26.40||10.00||3.16||-1.22||-214.63|
|Jaguar Health, Inc.||JAGX||4.35||5.00||3.45||0.07||-887.14|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of ...
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors
BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has added three new independent directors to its board: former Allergan ...
Covid posed a danger for ongoing drug clinical trials, but companies and researchers have made changes on the fly. Could ...
Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the February 2021 expiration ...
Less than two months after Allergan was officially taken in by AbbVie, ex-CEO Brent Saunders has landed on the board of ...
BRIEF-BridgeBio Pharma's ML Bio Announces Dosing Of First Subject In Phase 1 Trial For Limb Girdle Muscular Dystrophy Type 2I
June 11 (Reuters) - BridgeBio Pharma Inc: * BRIDGEBIO PHARMA’S ML BIO SOLUTIONS ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE 1 CLINICAL TRIAL OF BBP-418 FOR LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2I ...